Proteon Therapeutics, Inc. (PRTO) financial statements (2021 and earlier)

Company profile

Business Address 345 PARK AVENUE SOUTH
NEW YORK, NY 10010
State of Incorp.
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:16962242416584
Cash and cash equivalents16961921364069
Short-term investments   2152515
Other undisclosed cash, cash equivalents, and short-term investments 03(0)(0)00
Restricted cash and investments00     
Prepaid expense      1
Other undisclosed current assets111111(0)
Total current assets:16972343436785
Noncurrent Assets
Property, plant and equipment1 00000
Intangible assets, net (including goodwill)30      
Goodwill30      
Restricted cash and investments1 0    
Other noncurrent assets2  0010
Total noncurrent assets:34 00110
TOTAL ASSETS:20372444446885
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities3139543
Accounts payable1000111
Accrued liabilities2039531
Employee-related liabilities      1
Other liabilities     1 
Other undisclosed current liabilities0     (1)
Total current liabilities:3139542
Noncurrent Liabilities
Long-term debt and lease obligation1      
Operating lease, liability1 
Other undisclosed noncurrent liabilities(1)      
Total noncurrent liabilities:1      
Total liabilities:4139542
Stockholders' equity
Stockholders' equity attributable to parent, including:19962035386382
Common stock0 00000
Additional paid in capital246213209203198195192
Accumulated other comprehensive income (loss) 00(0) (0)(0)
Accumulated deficit(47)(225)(210)(190)(160)(131)(110)
Other undisclosed stockholders' equity attributable to parent 182222   
Total stockholders' equity:19962035386382
TOTAL LIABILITIES AND EQUITY:20372444446885

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Gross profit:      3
Operating expenses(34)(15)(21)(30)(29)(21)(11)
Operating loss:(34)(15)(21)(30)(29)(21)(8)
Nonoperating income (expense)00100(1)4
Investment income, nonoperating 000000
Other nonoperating income (expense)  00(0)(1)5
Interest and debt expense(0)     (1)
Loss from continuing operations before income taxes:(34)(15)(21)(30)(29)(21)(4)
Income tax benefit17     0
Loss before gain (loss) on sale of properties:(17)(15)(21)(30)(29)(21)(4)
Other undisclosed net loss(17)      
Net loss:(34)(15)(21)(30)(29)(21)(4)
Other undisclosed net income attributable to parent      1
Net loss attributable to parent:(34)(15)(21)(30)(29)(21)(3)
Preferred stock dividends and other adjustments   (7)  (6)
Net loss available to common stockholders, diluted:(34)(15)(21)(37)(29)(21)(10)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net loss:(34)(15)(21)(30)(29)(21)(4)
Other comprehensive loss      (3)
Comprehensive loss:(34)(15)(21)(30)(29)(21)(7)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent (0)0(0)0(0) 
Comprehensive loss, net of tax, attributable to parent:(34)(15)(21)(30)(29)(21)(7)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: